The present invention relates to a compound of the general formula (I):(see formula I)The compound of formula (I) is suitable for treating pulmonary fibrosis, suchas Idiopathicpulmonary fibrosis in a mammal. Furthermore the present invention concerns amethod ofmonitoring development or progression of pulmonary fibrosis in a humansubject, a methodof monitoring or predicting exacerbation of symptoms in a human subject withpulmonaryfibrosis as well as a method for treatment of pulmonary fibrosis, such asIdiopathicpulmonary fibrosis in a human subject having a galectin-3 level indicative ofpulmonary fibrosisor exacerbation of symptoms.
